liraglutide (liraglutide)
Overview of liraglutide
Liraglutide was approved by FDA (US) in 2010 as hypoglycemic subcutaneous drug. Liraglutide is a glucagon like peptide 1 (GLP-1) receptor agoinst. Liraglutide increases intracellular Cyclic AMP leading to insulin release in the presence of elevated glucose concentration.Liraglutide also decreases glucagon secretion and delays in gastric emptying time which resluts in lowering of blood glucose. Liraglutide is indicated for type II Diabetes Mellitus patients adjunct to diet and excercise to improve glycemic control
Indication of liraglutide
liraglutide is primarily indicated in conditions like Diabetes mellitus type-ii.
Contraindication of liraglutide
liraglutide is contraindicated in conditions like Thyroid cancer.
Side Effects of liraglutide
liraglutide produces potentially life-threatening effects which include Angioedema, Urticaria. which are responsible for the discontinuation of liraglutide therapy.,The signs and symptoms that are produced after the acute overdosage of liraglutide include Nausea & vomiting.,The symptomatic adverse reactions produced by liraglutide are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Diarrhea, Constipation, Rashes, Erythema, Nausea and vomiting, Hypertension, Sinusitis, Hypoglycemia, Back pain, Nasopharyngitis, Injection site reactions, influenza, urinary tract infection.
Precautions of liraglutide
Risk of thyroid cell tumors Serious hypoglycemia can occur when ligragutide is given with an insulin Risk of Pancreatitis